| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Tau, TAU, TAU_HUMAN, MAPT, MAPTL, Microtubule-associated protein tau, Microtubule associated protein tau, Microtubule associated protein tau isoform 4, Neurofibrillary tangle protein, Paired helical filament tau, Paired helical filament-tau, PHF tau, PHF-tau, DDPAC, FTDP 17, G protein beta1/gamma2 subunit interacting factor 1, MSTD, Mtapt, MTBT1, MTBT2, PPND, PPP1R103, Protein phosphatase 1 regulatory subunit 103, RNPTAU, AI413597, AW045860, FLJ31424, MGC134287, MGC138549, MGC156663 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | Human Recombinant Tau441 (2N4R), P301S mutant Protein Pre-formed Fibrils |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Tau is a microtubule-associated protein predominantly found in neuronal axons, where it stabilizes microtubules and supports axonal transport. In the adult human brain, six isoforms of tau are expressed, generated by alternative splicing of the MAPT gene. These isoforms contain either three (3R) or four (4R) microtubule-binding repeat domains, with 2N4R (Tau-441) representing the full-length form.
In healthy neurons, tau is tightly regulated. However, in neurodegenerative diseases known as tauopathies—including Alzheimer’s disease (AD), frontotemporal dementia, and progressive supranuclear palsy—tau becomes abnormally hyperphosphorylated. This modification reduces its affinity for microtubules, leading to the formation of insoluble neurofibrillary tangles (NFTs), a pathological hallmark of AD.
Mutations in the MAPT gene, such as P301S (encoded by exon 10), impair tau’s ability to bind microtubules and promote aggregation. These mutations are commonly used in transgenic models to study tau-mediated neurotoxicity, synaptic dysfunction, and neuronal death.
Tau pathology correlates strongly with cognitive decline in AD and is increasingly recognized as a driver of disease progression. As such, tau is a major focus of biomarker development and therapeutic targeting in neurodegenerative research.
A 1:1000 dilution of SMC-607 was sufficient for detection of Tau 2N4R P301S Fibril in 20 ug of Mouse Brain by ECL immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-607D — Size: 100 ug: Tau Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D, RRID: AB_2820306)
- SMC-607D-A390 — Size: 100 ug: Tau Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-A390, RRID: AB_2822515)
- SMC-607D-A488 — Size: 100 ug: Tau Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-A488, RRID: AB_2822516)
- SMC-607D-A594 — Size: 100 ug: Tau Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-A594, RRID: AB_2822518)
- SMC-607D-APC — Size: 100 ug: Tau Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-APC, RRID: AB_2822524)
- SMC-607D-BI — Size: 100 ug: Tau Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-BI, RRID: AB_2822526)
- SMC-607D-FITC — Size: 100 ug: Tau Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-FITC, RRID: AB_2822532)
- SMC-607D-HRP — Size: 100 ug: Tau Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-HRP, RRID: AB_2822533)
- SMC-607D-PCP — Size: 100 ug: Tau Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-PCP, RRID: AB_2822535)
- SMC-607D-RPE — Size: 100 ug: Tau Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607D-RPE, RRID: AB_2822536)
- SMC-607S — Size: 12 ug: Tau Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-607S, RRID: AB_2820306)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907)
3. Matsumoto, G. et al. (2018). Int J Mol Sci. 19, 1497.
4. Goedert, M. and Spillantini, M. G. (2017). Mol Brain. 10:18.
5. Bugiani, O. et al. (1999). J Neuropathol Exp Neurol. 58(6):667-77.